Covid – Can You Still Get COVID-19 After Vaccination?

Daniel Gusberti

October 7, 2022


If you are vaccinated against COVID-19, you are protected against the disease. However, if you get exposed to COVID-19 after getting the vaccination, you might be at risk for the virus. Therefore, getting tested for COVID-19 within three to five days after exposure is essential. You should also isolate yourself for ten days and wear a mask for at least 14 days.

Breakthrough COVID-19

The Breakthrough COVID-19 vaccine protects patients against the disease and prevents hospitalization and severe illness. Currently, there are three COVID-19 vaccines available in the U.S. The vaccine can prevent severe illness and even death in many cases. In addition, the COVID-19 vaccine has held its ground against new strains of the virus. However, no vaccine is perfect, and breakthrough infections are expected when new variants are discovered.

The symptoms of COVID-19 can be similar to flu or seasonal allergies. Therefore, it’s essential to get tested for the disease. PCR and antigen tests available at home will identify if you have COVID-19.

Symptoms of COVID-19 after vaccination

In a new study, researchers have looked at the symptoms of COVID-19 after vaccination. They teamed up with a health-science firm to analyze data from a group of people vaccinated with the virus. The results showed that vaccinated individuals had similar symptoms to non-vaccinated individuals. However, they suffered from them less acutely and for shorter periods. This may indicate that vaccinated individuals were less at risk of serious illness.

Booster vaccination effectively protected against COVID-19 infection in high-risk groups, although previous studies did not provide reliable data on how many high-risk individuals developed the serious illness after vaccination. High-risk groups exhibited higher rates of illness and mortality and were more likely to have a comorbid disease. The incidence of hospitalization and death was higher among high-risk subgroups, including immunocompromised individuals. In addition, the cumulative incidence of pneumonia associated with COVID-19 vaccination was similar in these high-risk groups.

Efficacy of COVID-19 vaccines

When developing a new COVID-19 vaccine, companies must prove its efficacy against the disease. Effectiveness is usually measured in terms of reduction in the risk of developing a severe infection. This is done by comparing the vaccination rate in a population with and without the virus. The study results are reported as relative risk reduction (RRR). Efficacy is also measured in terms of protection against the disease.

A review of published trials has found that COVID-19 vaccines are effective against severe and moderate COVID. However, vaccine efficacy in children aged 5-11 years was less than that in older adolescents. It is unclear how much the difference is because the younger children received the vaccine before the Omicron variant became dominant. However, vaccination did reduce hospitalizations associated with COVID-19 in this age group.

Risk of blood clots

The risk of blood clots after COVIR-19 vaccination is sporadic and not disproportionate to the overall risk of thrombosis in the general population. The risk of thrombosis following the vaccination is only seven cases per million women aged 18 to 49 years; the rate is much higher in women over 50. This rare but severe side effect must be considered carefully before the vaccine is recommended for women.

Early in the pandemic, a link between COVID-19 and blood clots was found. Blood clots in the arteries can lead to heart attacks or strokes. While patients with severe illnesses were more likely to develop blood clots, non-severe cases also occurred. However, the incidence of blood clots differed by risk factors and the severity of the COVID-19 infection.


Antiviral medications, called monoclonal antibodies, are available to treat mild to moderate COVID-19. These medicines effectively fight the virus and help prevent severe illness. They work by stimulating the immune system to recognize and respond more effectively to the virus. However, these medications may have side effects and interact with certain medications. Therefore, it is essential to seek the advice of your healthcare provider before beginning treatment.

Patients with high-risk factors for COVID-19 should consider getting tested to determine if they are at risk. These factors include age, obesity, and certain medical conditions that suppress the immune system. In these cases, a healthcare provider should recommend treatment. The disease can be life-threatening, so starting treatment as early as possible is essential. Treatment will usually consist of oral antiviral medication.